المؤلفون: Cecchini M; Department of Internal Medicine (Medical Oncology), Yale University School of Medicine, New Haven, CT, 06510, USA. Michael.cecchini@yale.edu., Cleary JM; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, 02215, USA., Shyr Y; Department of Biostatistics, Vanderbilt University, Nashville, TN, 37203, USA., Chao J; Department of Medical Oncology & Therapeutics Research, City of Hope, Duarte, CA, 91010, USA., Uboha N; Department of Medicine, University of Wisconsin, Madison, WI, 53792, USA., Cho M; Department of Medicine, University of California Irvine, Irvine, CA, 92868, USA., Shields A; Karmanos Cancer Institute, Wayne State University, Detroit, MI, 48201, USA., Pant S; Department of Gastrointestinal Medical Oncology, MD Anderson Cancer Center, Houston, TX, 77030, USA., Goff L; Department of Medicine, Vanderbilt-Ingram Cancer Center, Nashville, TN, 37203, USA., Spencer K; Department of Medicine, Perlmutter Cancer Center of NYU Langone Health and NYU Grossman School of Medicine, New York, NY, 10016, USA., Kim E; Department of Internal Medicine, University of California Davis, Davis, CA, 95817, USA., Stein S; Department of Internal Medicine (Medical Oncology), Yale University School of Medicine, New Haven, CT, 06510, USA., Kortmansky JS; Department of Internal Medicine (Medical Oncology), Yale University School of Medicine, New Haven, CT, 06510, USA., Canosa S; Department of Pathology, Yale University School of Medicine, New Haven, CT, 06510, USA., Sklar J; Department of Pathology, Yale University School of Medicine, New Haven, CT, 06510, USA., Swisher EM; Department of Obstetrics and Gynecology, University of Washington, Seattle, WA, 98195, USA., Radke M; Department of Obstetrics and Gynecology, University of Washington, Seattle, WA, 98195, USA., Ivy P; Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD, 20892, USA., Boerner S; Department of Internal Medicine (Medical Oncology), Yale University School of Medicine, New Haven, CT, 06510, USA., Durecki DE; Department of Internal Medicine (Medical Oncology), Yale University School of Medicine, New Haven, CT, 06510, USA., Hsu CY; Department of Biostatistics, Vanderbilt University, Nashville, TN, 37203, USA., LoRusso P; Department of Internal Medicine (Medical Oncology), Yale University School of Medicine, New Haven, CT, 06510, USA., Lacy J; Department of Internal Medicine (Medical Oncology), Yale University School of Medicine, New Haven, CT, 06510, USA.

المصدر: British journal of cancer [Br J Cancer] 2024 Feb; Vol. 130 (3), pp. 476-482. Date of Electronic Publication: 2023 Dec 22.

نوع المنشور: Clinical Trial, Phase II; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural

بيانات الدورية: Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-1827 (Electronic) Linking ISSN: 00070920 NLM ISO Abbreviation: Br J Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Stomach Neoplasms*/drug therapy , Stomach Neoplasms*/genetics , Adenocarcinoma*/drug therapy , Adenocarcinoma*/genetics , Esophageal Neoplasms* , Piperazines*, Humans ; Ramucirumab ; Phthalazines ; Esophagogastric Junction ; Antineoplastic Combined Chemotherapy Protocols/adverse effects

SCR Disease Name: Adenocarcinoma Of Esophagus

المؤلفون: Cecchini M; Department of Internal Medicine (Medical Oncology), Yale University School of Medicine, New Haven, Connecticut., Walther Z; Department of Pathology, Yale University School of Medicine, New Haven, Connecticut., Wei W; Department of Biostatistics, Yale School of Public Health, New Haven, Connecticut., Hafez N; Department of Internal Medicine (Medical Oncology), Yale University School of Medicine, New Haven, Connecticut., Pilat MJ; Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, Michigan., Boerner SA; Department of Internal Medicine (Medical Oncology), Yale University School of Medicine, New Haven, Connecticut., Durecki DE; Department of Internal Medicine (Medical Oncology), Yale University School of Medicine, New Haven, Connecticut., Eder JP; Department of Internal Medicine (Medical Oncology), Yale University School of Medicine, New Haven, Connecticut., Schalper KA; Department of Pathology, Yale University School of Medicine, New Haven, Connecticut., Chen AP; Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland., LoRusso P; Department of Internal Medicine (Medical Oncology), Yale University School of Medicine, New Haven, Connecticut.

المصدر: Cancer research communications [Cancer Res Commun] 2023 Jun 26; Vol. 3 (6), pp. 1113-1117. Date of Electronic Publication: 2023 Jun 26 (Print Publication: 2023).

نوع المنشور: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural

بيانات الدورية: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9918281580506676 Publication Model: eCollection Cited Medium: Internet ISSN: 2767-9764 (Electronic) Linking ISSN: 27679764 NLM ISO Abbreviation: Cancer Res Commun Subsets: MEDLINE

مواضيع طبية MeSH: Neoplasms*/drug therapy , Antineoplastic Agents*/therapeutic use, Humans ; Irinotecan/therapeutic use ; Benzimidazoles/adverse effects ; Poly(ADP-ribose) Polymerase Inhibitors/adverse effects

المؤلفون: Dytfeld D; University of Chicago, Chicago, IL, USA University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA Karol Marcinkowski University of Medical Sciences, Poznan, Poland., Jasielec J; University of Chicago, Chicago, IL, USA., Griffith KA; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA., Lebovic D; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA., Vesole DH; The John Theurer Cancer Center at Hackensack UMC, Hackensack, NJ, USA., Jagannath S; Mount Sinai Medical Center, New York, NY, USA., Al-Zoubi A; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA., Anderson T; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA., Detweiler-Short K; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA., Stockerl-Goldstein K; Washington University School of Medicine, St. Louis, MO, USA., Ahmed A; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA., Jobkar T; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA., Durecki DE; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA., McDonnell K; University of Chicago, Chicago, IL, USA., Mietzel M; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA., Couriel D; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA., Kaminski M; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA., Vij R; Washington University School of Medicine, St. Louis, MO, USA., Jakubowiak AJ; University of Chicago, Chicago, IL, USA University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA ajakubowiak@medicine.bsd.uchicago.edu.

المصدر: Haematologica [Haematologica] 2014 Sep; Vol. 99 (9), pp. e162-4. Date of Electronic Publication: 2014 Jun 27.

نوع المنشور: Letter; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Ferrata Storti Foundation Country of Publication: Italy NLM ID: 0417435 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1592-8721 (Electronic) Linking ISSN: 03906078 NLM ISO Abbreviation: Haematologica Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents/*therapeutic use , Dexamethasone/*therapeutic use , Multiple Myeloma/*drug therapy , Oligopeptides/*therapeutic use , Thalidomide/*analogs & derivatives, Aged ; Aged, 80 and over ; Clinical Trials as Topic ; Drug Administration Schedule ; Female ; Humans ; Lenalidomide ; Male ; Multiple Myeloma/mortality ; Multiple Myeloma/pathology ; Survival Analysis ; Thalidomide/therapeutic use ; Treatment Outcome

المؤلفون: Jakubowiak AJ; University of Chicago Medical Center, Chicago, IL 60637-6613, USA. ajakubowiak@medicine.bsd.uchicago.edu, Dytfeld D, Griffith KA, Lebovic D, Vesole DH, Jagannath S, Al-Zoubi A, Anderson T, Nordgren B, Detweiler-Short K, Stockerl-Goldstein K, Ahmed A, Jobkar T, Durecki DE, McDonnell K, Mietzel M, Couriel D, Kaminski M, Vij R

المصدر: Blood [Blood] 2012 Aug 30; Vol. 120 (9), pp. 1801-9. Date of Electronic Publication: 2012 Jun 04.

نوع المنشور: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Hematopoietic Stem Cell Transplantation/*methods , Multiple Myeloma/*therapy, Adult ; Aged ; Aged, 80 and over ; Anemia/etiology ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Combined Modality Therapy ; Dexamethasone/administration & dosage ; Dexamethasone/adverse effects ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Female ; Hematopoietic Stem Cell Transplantation/adverse effects ; Humans ; Hyperglycemia/etiology ; Hypophosphatemia/etiology ; Kaplan-Meier Estimate ; Lenalidomide ; Male ; Middle Aged ; Oligopeptides/administration & dosage ; Oligopeptides/adverse effects ; Thalidomide/administration & dosage ; Thalidomide/adverse effects ; Thalidomide/analogs & derivatives ; Transplantation, Autologous ; Treatment Outcome